Key facts
- Swing Therapeutics’s last known valuation is $24.3M (Aug 2025).
- It has raised $31.4M across 4 recorded rounds; the latest was Seed Round ($3.3M) in Aug 2025.
- Notable investors include Alumni Ventures, Mana Ventures, Gaingels, Endless Frontier Labs, AME Cloud Ventures — 10 tracked in total.
- Swing Therapeutics has filed 4 Form Ds with the SEC since 2022, most recently Sep 2025 ($3.3M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Swing Therapeutics
Funding rounds
4 roundsAbout Swing Therapeutics
Developer of novel prescription digital therapeutics designed to empower people to live joyful and vibrant lives. The company's therapeutics offer evidence-based, transformative digital treatments, enabling patients and clinics to regain control of illnesses.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 22
- Website
- swingtherapeutics.com/
- Ownership
- Privately Held (backing)
Swing Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Swing Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Swing Therapeutics in its N-PORT filings yet. We sweep new filings monthly.